In today’s briefing:
- Quiddity Flow Expectations HSTECH Mar 23: Two Index Changes Possible
- STAR50 Index Rebalance Preview: 5 Changes Forecast as Review Period Ends
- Tencent (700 HK): Risen 100% in Three Months, But Still 21%~44% Upside
- Greatview Aseptic (468 HK): Xinjufeng Technology Acquires Jardine Matheson’s Stake
- Evergrande : Not Legit
- Xpeng: Accelerated Model Launch Campaign May Surprise
- Shanghai MicroPort MedBot Group (2252.HK) – Recognize the Reality but Don’t Give up Hope
- Aequitas ASEAN Placements Bookrunner Performance (2019-2022)
- Morning Views Asia:
- China’s Green Loan Market: Fifty Shades of Green
Quiddity Flow Expectations HSTECH Mar 23: Two Index Changes Possible
- In this insight, we take a look at the potential index changes and the resultant capping flows for the Hang Seng Tech Index (HSTECH INDEX) in March 2023.
- According to our estimation, there could be two changes for the HSTECH in March 2023 and there could be one-way index flows of US$365mn.
- The final index changes along with indicative capping and index weights could be published in Mid/Late-February 2023 and implemented in early-March 2023.
STAR50 Index Rebalance Preview: 5 Changes Forecast as Review Period Ends
- The review period for the March rebalance ends today. We forecast 2 changes using a 12-month minimum listing history, and 5 changes using a 6-month minimum listing history.
- We expect the index committee to continue using a 6-month minimum listing history. The impact on the potential deletes is a lot higher than the impact on the potential adds.
- With 5 changes to the index, estimated one-way turnover is 5.1% resulting in a one-way trade of CNY 4,549m. There is a reasonably large reverse funding trade.
Tencent (700 HK): Risen 100% in Three Months, But Still 21%~44% Upside
- We believe total revenue growth rate will accelerate from 4Q22 and grow by 9% in 2023.
- We believe the operating margin will be stable from 4Q22 to 2Q23, but the margin will climb up from 3Q23.
- We believe that EPS will increase by 16% and the stock will have an upside of 21%~44%.
Greatview Aseptic (468 HK): Xinjufeng Technology Acquires Jardine Matheson’s Stake
- Shandong Xinjufeng Technology Packaging (301296 CH) agreed to acquire Jardine Matheson Holdings (JM SP)’s 28.22% stake in Greatview Aseptic Packaging (468 HK) at HK$2.65 per share.
- Post-Completion, Xinjufeng will be the largest shareholder. As Xinjufeng’s shareholding will remain below the 30% voting threshold, the transaction will NOT result in a mandatory general offer.
- The transaction price, which is a 22.7% premium to the last close, highlights Greatview’s value. Greatview’s forward P/E multiple is undemanding in comparison to peer P/E multiples.
Evergrande : Not Legit
- The company has defaulted since 2021 and has already missed a few payments as well as the deadline to deliver a restructuring blueprint at the end of 2022.
- We believe the Chinese government is looking now to rescue developers (such as Country Garden) which are seen as systemically important.
- We are of the opinion that the sector is not investable for the general public in 2023 and only the Distressed specialists should endeavor investing in Chinese high-yield property developers.
Xpeng: Accelerated Model Launch Campaign May Surprise
- Xpeng has announced it is speeding up its new model launch pipeline by launching 5 new models this year
- If all go to plan, Xpeng’s sales may hit 30k vehicles/month end of ’23 or early ’24
- The appointment of new President from ICE sector may lead to some market confusion on management and branding in the short term
Shanghai MicroPort MedBot Group (2252.HK) – Recognize the Reality but Don’t Give up Hope
- New policy about surgical robots was released, which is conducive to the promotion and popularization of surgical robots in China. However, the situation is not as simple as it seems.
- We deep dive the business environment of surgical robots in China.Even with favorable policies, both surgical robot systems and consumables have to reduce price largely so as to be affordable.
- It’s difficult to make profits in China. Medbot could lose money for quite some time.Without solid internationalization, the rally cannot be sustained for a long time only by policy catalyst.
Aequitas ASEAN Placements Bookrunner Performance (2019-2022)
- In this note, we will take a look at the performance of bookrunners for ASEAN placements from 2019-2022.
- The following dataset includes all ASEAN placements above US$100m for the period of Calendar Years 2019-2022, which amounted to a total of 54 deals.
- The deals you see in this note are based on our historical placements tracker. Feel free to drop us a message for additional information on any of these placements.
Morning Views Asia:
Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.
China’s Green Loan Market: Fifty Shades of Green
- The PBOC has extended the use of its policy tools to support the green loan industry as part of the country’s’ drive towards carbon neutrality.
- China’s green loan market is already the largest in the world, if you agree with its definitions and can look past its limitations.
- The state of green finance matters to investors, and not just those with explicit ESG mandates. We look at the potential pitfalls in the China.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars